Showcases Stock ranks Forex

Axonics Inc (AXNX)
56.04  0.74 (1.34%) 03-24 16:00
Open: 56.46 Pre. Close: 55.3
High: 57.06 Low: 55.03
Volume: 636,551 Market Cap: 2,800(M)
Stock Technical Analysis
Target: Six months: 67.81
One year: 72.58
Support: Support1: 51.44
Support2: 42.80
Resistance: Resistance1: 58.05
Resistance2: 62.14
Pivot: 55.57
Moving Averages: MA(5): 57.32
MA(20): 56.51
MA(100): 61.08
MA(250): 62.26
MACD: MACD(12,26): -0.51
Signal(12,26,9): -0.77
%K %D: %K(14,3): 41.60
%D(3): 53.72
RSI: RSI(14): 47.43
52-Week: High: 79.92
Low: 38.41
Change(%): -10.3
Average Vol(K): 3-Month: 687
10-Days: 660
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 57.089 - 57.37 57.37 - 57.655
Low: 54.377 - 54.665 54.665 - 54.957
Close: 55.575 - 56.033 56.033 - 56.498
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ AXNX ] has closed below upper band by 44.7%. Bollinger Bands are 5.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Stock chart
Stock News
Sun, 26 Mar 2023
Axonics, Inc. (NASDAQ:AXNX) Receives Consensus Rating of ... - MarketBeat

Sat, 25 Mar 2023
Robeco Institutional Asset Management B.V. acquires new shares of ... - Best Stocks

Sat, 25 Mar 2023
Axonics (NASDAQ:AXNX) Upgraded at Needham & Company LLC - MarketBeat

Fri, 24 Mar 2023
Robeco Institutional Asset Management B.V. Purchases New Stake ... - MarketBeat

Tue, 14 Mar 2023
Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Advisory Research Inc. - MarketBeat

Fri, 10 Mar 2023
Vanguard Group Now Owns 10.28% of Axonics Modulation ... - Nasdaq

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. (M) 49.96
Shares Float (M) 49.49
% Held by Insiders 0.82
% Held by Institutions 103.36
Shares Short (K) 3930
Shares Short Prior Month (K) 3490
Stock Financials
EPS -1.400
Book Value (p.s.) 11.510
Profit Margin -21.81
Operating Margin -15.38
Return on Assets (ttm) -4.4
Return on Equity (ttm) -11.3
Qtrly Rev. Growth 61.7
Gross Profit (p.s.) 3.956
Sales Per Share 5.478
EBITDA (p.s.) -0.608
Qtrly Earnings Growth
Operating Cash Flow (M) 3.19
Levered Free Cash Flow (M) 45.45
Stock Valuation
PE Ratio -40.03
PEG Ratio -1.41
Price to Book value 4.87
Price to Sales 10.23
Price to Cash Flow 877.67
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android